The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan

American Journal of Medicine

Volumn 104, Issue 5 A, 1998, Pages 7S-10S

  Hiramatsu, Keiichi ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMPHENICOL DERIVATIVE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; HABEKACIN; METICILLIN; N ACETYLGLUCOSAMINE; PENICILLIN BINDING PROTEIN; PENICILLIN DERIVATIVE; PEPTIDOGLYCAN; STREPTOGRAMIN; SULTAMICILLIN; TEICOPLANIN; TETRACYCLINE DERIVATIVE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; COLONY FORMING UNIT; CONFERENCE PAPER; GENE; GENE TRANSFER; HOSPITAL INFECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; JAPAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

EID: 0032577607     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00149-1     Document Type: Conference Paper

References (25)

1. Edmond M.B., Wenzel R.P., Pasculle A.W. Vancomycin-resistant Staphylococcus aureus perspectives on measures needed for control . Ann Intern Med. 124:1996;329-334.
2. Reduced susceptibility of Staphylococcus aureus to vancomycin - Japan 1996. MMWR. 46:1997;624-626.
3. Hashimoto H., Inoue M., Hayashi I. A survey of Staphylococcus aureus for typing and drug-resistance in various areas of Japan during 1992 and 1993. Jpn J Antibiot. 47:1994;618-626.
4. Aoki Y. Therapeutic strategy for MRSA infections. Ngeow Y.-F., Hiramatsu K. ASEAN-Japan Seminar Workbook on Hospital Infection. 1995;47-56 University of Malaya Press, Kuala Lumpur.
5. Shimada K., Kobayashi H., Sunagawa K., Inamatsu T., Yamaguchi K. Clinical summary of intravenous use of vancomycin hydrochloride for severe infection caused by methicillin-resistant Staphylococcus aureus. Jpn J Chemother. 43:1995;1048-1061.
6. Yoshida T., Hiramatsu K. Potent in vitro bactericidal activity of polymyxin B against methicillin-resistant Staphylococcus aureus (MRSA). Microbiol Immunol. 37:1993;853-859.
7. Niitsuma K., Saito M. Vancomycin inhalation therapy - a pharmacokinetic and clinical study of vancomycin. Antibiot Chemother. 122:1996;123-135.
8. Torres J.R., Sanders C.V., Lewis A.C. Vancomycin concentration in human tissues preliminary report . J Antimicrob Chemother. 5:1979;475-477.
9. Gopal V., Bisno A.L., Silverblatt F.J. Failure of vancomycin treatment in Staphylococcus aureus endocarditis. JAMA. 236:1976;1604-1606.
10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed Approved standard M7-A4 . 1997;National Committee for Clinical Laboratory Standards, Villanova, PA.
11. Sanyal D., Johnson A.P., George R.C., Cookson B.D., Williams A.J. Peritonitis due to vancomycin-resistant Staphylococcus epidermidis. (Abstr.). Lancet. 337:1991;54.
12. Schwalbe R.S., Stapleton J.T., Gilligan P.H. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med. 316:1987;927-931.
13. Veach L.A., Pfaller M.A., Barrett M., Koontz F.P., Wenzel R.P. Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection. J Clin Microbiol. 28:1990;2064-2068.
14. Noble W.C., Virani Z., Cree R.G.A. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett. 93:1992;195-198.
15. Poyart C., Pierre C., Quesne G., Benedicte P., Berche P., Trieu-Cuot P. Emergence of vancomycin resistance in the genus Streptococcus characterization of a vanB transferable determinant in Streptococcus bovis . Antimicrob Agents Chemother. 41:1997;24-29.
16. Fontana R., Ligozzi M., Pedrotti C., Padovaniem E.M., Cornaglia G. Vancomycin-resistant Bacillus circulans carrying the vanA gene responsible for vancomycin resistance in enterococci. Eur J Clin Microbiol Infec Dis. 16:1997;473-474.
17. Sieradzki K., Tomasz A. A highly vancomycin-resistant laboratory mutant of Staphylococcus aureus. FEMS Microbiol Lett. Sep 1;142:1996;161-166.
18. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., Tenover E.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 40:1997;135-136.
19. Tabata M., Takada T., Hirano F., Hiramatsu K. Combined bactericidal effect of arbekacin and sulbactam/ampicillin on MRSA. Deutsche Medizinische Wochenschrift. (Japanese ed). 18:1996;1549-1552.
20. Hanaki H., Labischinski H., Sasaki K., Kuwahara-Arai K., Inaba Y., Hiramatsu K. Mechanism of vancomycin resistance in MRSA strain Mu50. Jpn J Antibiot. 51:1998;237-247.
21. Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR. 1997;46:626-628,635.
22. Hiramatsu K., Aritaka N., Hanaki H., et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 350:1997;1668-1671.
23. Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. MMWR. 46:1997;765-766.
24. Update Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997 . MMWR. 46:1997;813-815.
25. Recommendations for preventing the spread of vancomycin resistance. MMWR. 44:1995;1-13.